Overexpression of the p73 gene is a novel finding in high-risk B-cell chronic lymphocytic leukemia

U. Novak,1 T. J. Grob,1 G. Baskaynak,2 U. R. Peters,2 S. Aebi,1 D. Zwahlen,1 M. P. Tschan,1 K.-A. Kreuzer,2 E. Oppliger Leibundgut,1 J.-F. Cajot,1 A. Tobler1 & M. F. Fey1

1University and Inselspital, Department of Clinical Research. Medical Oncology/Haematology, Berne, Switzerland; 2Charité/Virchow-Clinic, Humboldt-University, Department of Haematology/Oncology, Berlin, Germany

Summary

The p73 protein shares structural and functional similarities with the tumour-suppressor p53, but its role in neoplastic transformation is unknown. Alternative splicing leads to the expression of at least nine p73 C-terminal mRNA splice variants (α, β, γ, δ, ε, ζ, η, η1, θ). In this survey, we analyse the expression of p73 by real-time quantitative RT–PCR, its known C-terminal variants with an RT–PCR-Southern technique and by Western blot in samples of 51 patients with B-CLL, normal B lymphocytes from eight individuals, and five haematopoetic cell lines. p73α protein expression positively correlated with higher risk B-CLL stages (P = 0.046)

Introduction

B-cell chronic lymphocytic leukaemia (B-CLL), the most frequent adult leukaemia in Western countries, results from slow clonal accumulation of neoplastic, and mature appearing B lymphocytes. Most cells are in the G0/G1 phase of the cell cycle and therefore do not proliferate [1]. B-CLL is a heterogeneous disease, mainly characterized by failed programmed cell death [2]. So far, only few genes involved in its molecular pathology have been identified [3]. In B-CLL, p53-inactivating mutations are associated with an excess of prolymphocytes, poor response to treatment with purine analogues, and poor survival. Such mutations have been reported for a small percentage of B-CLL patients only (9%–15%) [3, 4].

p73 is a gene with structural and functional similarities to p53 [5]. At least nine different p73 C-terminal mRNA splice variants (α, β, γ, δ, ε, ζ, η, η1, θ) are known. The variants β to θ result in truncated forms of the C-terminal full length p73α protein; variants β, γ, δ, ε, η1, and θ use an alternative reading frame leading to the formation of different C-termini compared with p73α [6–8]. The p73 C-terminal mRNA splice variants differ in vitro in their potential to activate p53-responsive genes such as p21Waf/Cip1 and BAX [6]. The structural homology of p73 with p53 as well as its localization on chromosome 1p36.1, a region frequently deleted in various tumours [5] initially suggested that p73 might also act as a tumour suppressor. Indeed, overexpression of p73 in vitro can induce irreversible cell cycle and growth arrest [5, 6, 9], and promote apoptosis, even in the absence of p53 [10]. Despite these similarities, several lines of evidence suggest a functional difference between p73 and p53. The genes differ in their interaction with viral oncoproteins [11]. Mdm2 inhibits p73, but in contrast to p53 without degradation [12]. DNA damage induces p73, albeit through a distinct, p53-independent pathway [11]. In contrast to p53, mutations of the p73 gene are very rare in human cancers including haematological malignancies [11, 13–15], and p73-knockout-mice do not develop spontaneous tumours [16]. Finally, p73 mRNA expression is increased rather than absent in a variety of tumours relative to their homologous normal tissues [11]. The overexpression of the p73 gene may be a mechanism of p53-inactivation in p53 wild-type tumours through competition for DNA binding sites [17]. Although the role of p73 in tumorigenesis is unknown, it was shown that the high expression of p73 is positively correlated with poor prognosis in hepatocellular carcinoma [18] and with progression of bladder tumours [19]. Data on p73 expression in B-CLL have not yet been published. We have therefore studied the expression of p73 including its known C-terminal splice variants in B-CLL patients.

Key words: apoptosis, B-CLL, overexpression, p53, p73
Materials and methods

Patient samples, normal controls, and cell lines

Peripheral blood samples from 51 patients with typical B-CLL according to standard clinical and laboratory findings [20] including a minimal Matutes-Score of four [21] were prospectively collected with informed consent. The mean age was 65 years (range 38-85) and the male to female ratio was 1.83:1. B-CLL were classified according to the modified Rai-stage [22], and patients with autoimmune anaemia and/or thrombocytopenia were classified separately as high risk/immune cases [23]. Twelve of fifty-one (23.5%) patients were in the high risk, 6 of 51 (11.8%) in the intermediate risk, and 6 of 51 (11.8%) in the low risk group. At the time of sampling, 18 of 51 patients (35.3%) had never been treated. 25 of 51 patients (49%) had received treatment > two months prior to sample collection, and 8 of 51 patients (15%) were under treatment with different regimens. Malignant B-lymphocytes were isolated by density gradient centrifugation on Lymphoprep (Nycomed Pharma AS. Oslo, Norway). A purity of >90% mononuclear cells was obtained as assessed microscopically. Normal CD19+-B-lymphocytes were isolated from peripheral blood (Figure 2, nos. 1–3, 5), normal spleens (nos. 4, 6 and 7) and tonsils (no. 8) were kind gifts from S. Miescher, Berne, Switzerland. Positive selection was performed using magnetic beads coated with anti-CD19 antibodies according to the manufacturer’s protocol (Dynal A.S. Oslo, Norway) with a purity of >90% measured by flow cytometry. Three lymphoid cell lines and two myeloid leukaemic cell lines (Kasumi-1 (AML), K562 (CML) in blast crisis) were obtained from the German Collection of Microorganisms and Cell Cultures (DSMZ: Braunschweig, Germany) and were grown in RPMI-1640 (Sigma; St. Louis, Missouri) with 10% FCS.

RNA extraction, RT–PCR and real-time quantitative PCR

Total RNA was extracted using the RNeasy Mini Kit® (Qiagen. Basel, Switzerland). Synthesis of first strand cDNA and the real-time quantitative RT-PCR were performed as previously described [24, 25]. Briefly, total p73 was amplified by PCR using primers in exons 5 and 6 of p73. The TaqMan probe hybridized to a sequence of exon 6. The p73 isoforms a and b were synthesized in vitro by TNT T7 Quick Coupled Transcription/Translation System according to the manufacturer’s protocol (Promega, Wallisellen, Switzerland) from p73a- and b-HA-pcDNA3 plasmids (kind gifts from V. Delaurenzi, Rome, Italy [6]), and were used as standards for the Western blot. To assess protein quality of the patient samples, 50 µg of protein was Western blotted and detected with a rabbit polyclonal antibody against actin (A2066, Sigma, Buchs, Switzerland).

Statistical analysis

The expression of p73 was compared by t-tests and analysis of variance of the log-transformed ratios of p73 and β-actin. The data were tested for normality by constructing Q-Q-plots and with the Komolgorov–Smirnov procedure, and for equal variances with the Levene test. Tukey’s least significant difference was used for the post-hoc comparison of individual risk groups. Categorical data were analysed in contingency tables and tested for significant differences by χ² and by Fisher’s exact test as appropriate. Spearman’s rank correlation was used for correlation coefficients. All high risk/immune cases were excluded from the correlation analysis since this group can not be ordered appropriately according to the modified Rai staging system [23, 27]. SPSS for Windows 8.0 was used for the calculations.

Results

Total p73 mRNA expression is significantly increased in B-CLL

Total p73 mRNA expression was measured quantitatively by real-time RT–PCR using p73 primers spanning exon 5 and 6, a region without any known splice sites [6–8]. The expression of total p73 mRNA was significantly higher in the 51 B-CLL patient samples compared to a population of normal CD19+-B-lymphocytes obtained from eight individuals (Figure 1, P = 0.01). Among particular B-CLL risk groups, the expression of total p73 mRNA was higher in the intermediate risk (P = 0.013) and in the high risk B-CLL group (P = 0.007) than in normal B-lymphocytes, but there was no difference between the low risk and the high risk/immune group (data not shown in Figure 1). The cell lines JVM-2 and K562 expressed high levels of p73 mRNA whereas expression was very low or undetectable in RPMI-8402, Kasumi-1 and Jurkat (data not shown).

![Figure 1. Absolute total p73 and β-actin RNA transcript numbers as assessed by real-time quantitative RT–PCR in a population of normal CD19+- B-lymphocytes and B-CLL samples. Results are depicted as the 95% confidential interval (CI) of the ratio of log values of the mean. Total p73 mRNA expression in B-CLL (all risk groups) is significantly higher than in normal B-lymphocytes (P = 0.001).](image-url)
The expression of p73 C-terminal mRNA splice variants is biased

The investigation of p73 C-terminal mRNA splice variants by RT-PCR showed that many different variants were expressed in normal and malignant samples. The majority of both B-CLL and normal B-lymphocyte samples expressed the larger p73 C-terminal splice variants α, β, and ε (Table 1 and Figure 2). The ζ variant was detected in a subset of B-CLL (10 of 51) and normal B-lymphocytes (1 of 8) only. The γ variant was more frequently expressed in normal B-lymphocytes than in B-CLL (P = 0.041) as were the shorter mRNA splice variants θ (P < 0.001) and η (P = 0.033). Table 1 summarises the expression of p73 mRNA C-terminal splice variants in the lymphoid and the myeloid cell lines included in our study. In contrast to published data [14], RPMI-8402 was found to express p73α mRNA, and Kasumi-1 expressed the p73 mRNA variants α and β (Table 1).

p73α protein expression is positively correlated with higher risk B-CLL stages

p73 protein expression was investigated by Western blot using a rabbit polyclonal antibody [5]. We detected the

Table 1. Expression of the p73 gene in a population of normal CD19+-B-lymphocytes, patients with B-CLL, and cell lines. See ‘Materials and methods’ for details about different B-CLL risk groups.

<table>
<thead>
<tr>
<th>p73 C-terminal mRNA splice variants</th>
<th>p73 protein analysis</th>
</tr>
</thead>
<tbody>
<tr>
<td>No. of samples</td>
<td>α</td>
</tr>
<tr>
<td>---</td>
<td>---</td>
</tr>
<tr>
<td>Normal control B-lymphocytes</td>
<td>8</td>
</tr>
<tr>
<td>B-CLL</td>
<td></td>
</tr>
<tr>
<td>Low risk</td>
<td>6</td>
</tr>
<tr>
<td>Intermediate risk</td>
<td>27</td>
</tr>
<tr>
<td>High risk/immune</td>
<td>6</td>
</tr>
<tr>
<td>High risk</td>
<td>12</td>
</tr>
<tr>
<td>Total B-CLL</td>
<td>51</td>
</tr>
<tr>
<td>Cell lines</td>
<td></td>
</tr>
<tr>
<td>JVM-2</td>
<td>X</td>
</tr>
<tr>
<td>RPM1-8402</td>
<td>X</td>
</tr>
<tr>
<td>Jurkat</td>
<td>X</td>
</tr>
<tr>
<td>Kasumi-1</td>
<td>X</td>
</tr>
<tr>
<td>K562n</td>
<td>X</td>
</tr>
</tbody>
</table>

*Number of samples in which a particular C-terminal mRNA splice variant or protein was detected; cell lines: X = detected; O = not detected.

In addition to p73α as shown in Figure 2, p73 mRNA C-terminal splice variants γ (P = 0.041), θ (P < 0.001), and the η (P = 0.033) prevailed in normal B-lymphocytes. Prevalent detection of the p73α protein in B-CLL samples compared to normal B-lymphocytes (P = 0.008) and positive correlation with higher risk B-CLL stages (P = 0.046).
p73α protein in 33 of 51 B-CLL patient samples, but only in one of eight samples of normal B-lymphocytes ($P = 0.008$). Ten of twelve samples from high risk, but only two of six samples from low risk B-CLL patients expressed detectable levels of the p73α protein (Table 1 and Figure 2). Sixteen of 51 B-CLL and 7 of 8 B-lymphocyte samples expressed total p73 mRNA but no p73α protein, and in 2 of 51 B-CLL samples, neither was found. Detection of the p73α protein was positively correlated with higher risk B-CLL stages ($P = 0.046$).

Western blot analysis revealed a complex pattern of proteins (Table 1, Figure 2). The p73α protein was identified by its comigration with the in vitro translated p73β product (data not shown). None of the additional smaller bands comigrated with in vitro translated p73β which is also detected by the polyclonal antibody used (data not shown). In normal B-lymphocyte samples, a band of approx. 56 kD was present and was the only signal in 7 of 8 B-lymphocyte samples (Figure 2). This band was not exclusive to normal B-lymphocytes, but was also detected in B-CLL samples. In a subset of B-CLL samples of different risk groups, additional bands were detected in the absence of p73α (data not shown). The polyclonal antibody did not detect any proteins in the Kasumi-1 and the Jurkat cell lines which both express p73 mRNA at very low or undetectable levels as measured by real-time RT-PCR (data not shown).

Discussion

The results of this survey on the expression of p73 in B-CLL and normal CD19+- B-lymphocytes have revealed several novel features. In B-CLL, total p73 mRNA expression is significantly higher than in a normal B-lymphocyte population. A detailed analysis of the p73 C-terminal mRNA splice variants yields a biased expression pattern since the shorter p73 variants $\gamma$, $\delta$, and $\eta$ prevail in the normal B-lymphocyte population studied. p73α protein expression is significantly more frequent in B-CLL samples than in normal B-lymphocytes. Importantly, the expression of the p73α protein is positively correlated with higher risk B-CLL stages.

It was suggested that p73 acts as a tumour suppressor gene in ALL and Burkitt’s lymphoma and loss of its function would contribute to the development and the progression of such lymphoid neoplasms [8, 13, 14]. In contrast to these reports and in agreement with prior investigations in hepatocellular carcinoma [18] and bladder cancer [19], we have shown that in B-CLL, p73 expression is positively correlated with disease progression. This supports a possible oncogenic role of p73 in B-CLL.

The differences in the expression pattern of p73 between B-CLL, B-NHL and ALL may reflect differences in the biology of these groups of lymphoid malignancies. A link of the expression of the p73 gene to lymphoid differentiation is possible. The p73 gene is overexpressed in progressive B-CLL which is characterized by an accumulation of non-proliferating, senescent cells with disrupted apoptosis [2, 28]. In mature ALL, lack of p73 expression was suggested to contribute to the high proliferation rate [8]. p73 overexpression was initially shown to induce cell cycle and growth arrest as well as apoptosis in a series of cell lines [5, 6, 10]. Interestingly, recent reports on other cell lines confirmed the induction of cell cycle and growth arrest by overexpression of p73, but without apoptosis and in the presence of replicative senescence [9, 29]. Thus, the effect of p73 expression may be tissue-specific [5, 6, 30]. This may partially explain the apparent paradox that this gene is overexpressed in a variety of malignancies with disrupted apoptosis including B-CLL whilst inducing apoptosis in other cell types.

Earlier reports on malignancies other than B-CLL suggested that instability in the splicing of p73 exons preferentially occurs in cancer cells [11, 26]. We found that various p73 mRNA splice variants are expressed in both B-CLL and normal B-lymphocyte samples, but in different patterns. Shorter p73 mRNA splice variants prevailed in normal B-lymphocytes, although none of the p73 variants was restricted to either normal or malignant samples in our series. The shorter p73 splice variants such as $\gamma$, $\delta$, $\eta$, and $\eta_1$ lack the p73 C-terminal transactivation domain and the region of homology with the p53 oligomerization domain [8]. Some of the p73 variants exhibit p53-like functions or inhibit p53 while others may carry out yet unknown p73-specific functions [31]. In addition to the C-terminal splice variants, 2 different N-terminal p73 mRNA variants have recently been described [5, 16]. In mice, one of them, the ANp73 variant, was shown to act as a dominant negative inhibitor of p73α and p53 [16, 32]. These data suggest that the balance of expressed p73 variants may determine the function of the protein. E2F-1 is a transcriptional factor which can act as an oncogene or a tumour-suppressor gene [33]. The recently reported interactions of p73 with E2F1 [33] will help to clarify the role of p73 as a pro- or antiapoptotic actor in malignant diseases.

Earlier investigations on p73 mRNA expression in clinical samples have shown that p73 is overexpressed in a variety of malignancies with respect to their normal cellular counterparts [11, 25, 26]. Our data suggest that this is true for B-CLL with respect to normal CD19+- B-lymphocytes. Expression of the p73 gene may differ between various other subpopulations of B cells including CD5+- B-cells, which have been purported to represent normal counterparts of B-CLL cells [34, 35]. A comprehensive survey of p73 expression in all normal B-cell subtypes as well as other B-cell malignancies expressing the CD5 marker such as mantle cell lymphomas would be of some interest and warrant further investigation. Overexpression of the p73 gene in B-CLL is unlikely to be linked to treatment since only a minority of our
patients (8 of 51) were under treatment at the time of sample collection and the regimens did not contain drugs known to up-regulate p73 [11].

In agreement with prior reports [5, 12, 24, 25], p73 protein western analysis revealed the presence of several additional protein bands in all types of samples included in our series (Table 1, Figure 2). To investigate the nature of these additional proteins, we treated three different cell lines (JVM-2, MCF-7, and Calu-1) with N-acetyl-leucinyl-leucinyl-norleucinal (LNNL, MG-101, Sigma; Buchs, Switzerland) which inhibits ubiquitin-dependent protein degradation by the proteasome [12]. Evidence for protein degradation was only found in the JVM-2 cell line. The treatment with LNNL led to a transient band shift in JVM-2 as previously shown for other cell lines [12] (data not shown). The additional protein bands seen are currently under investigation, and may represent either p73 variants or posttranscriptional modifications of p73. New antibodies are needed to identify all known p73 variants.

In summary, we conclude that the accumulation of p73, the expression pattern of particular p73 variants and its link to progression may play a distinct role in the molecular pathology B-CLL.

Acknowledgements

We express our appreciation to Mrs. M. Oestreichner and B. Hugi for excellent technical assistance, and to A. Marti and J. Schwalier for critical review of the manuscript. We thank D. Caput for the anti-p73 rabbit polyclonal serum, V. Delaurensi for the p73 plasmids, and S. Miescher for the spleen and tonsil samples. This work was supported by grants from the Swiss National Foundation (3100-043458.95/1), from the Swiss Cancer League (KFS 156-9-1995), the Ursula-Hecht-Stiftung and the Deutsche José Carreras-Leukamie-Stiftung.

References


Received 2 November 2000; accepted 26 March 2001.

Correspondence to:
M. F. Fey, MD
Institute of Medical Oncology
University of Berne, Inselspital
3010 Berne
Switzerland
E-mail: martin.fey@insel.ch